ADA-409

About Aranda Pharma

Aranda Pharma is a private, preclinical-stage biotech developing topical androgen receptor inhibitors for dermatological conditions. Its lead program, ADA-308, targets the large and underserved markets of androgenetic alopecia (AGA) and acne with a potential best-in-class profile emphasizing local efficacy and a clean systemic safety profile. The company is based in Finland and is advancing towards regulatory studies, with a secondary brain disease program, ADA-409, in earlier discovery. Aranda represents a focused play on dermatology with a novel mechanism addressing a core hormonal pathway.

Therapeutic Areas